Dfn-15
Back Pain
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Phase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Back Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxycodone Grünenthal GmbH | Phase 4 | BBB |
Bxcl501 Medical College of Wisconsin | Phase 4 | BB |
Glycopyrrolate Medical College of Wisconsin | Phase 4 | BB |
NEPENTHE MedtronicNeuro | Phase 4 | BB |
LIDOCAINE Medical College of Wisconsin | Phase 4 | BB |
View all 41 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →